MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

[ad_1] MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of ‘France 2030’, led by the Health Innovation…

Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…